Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
Nabil Seery, Sifat Sharmin, Vivien Li, et al.
CNS Drugs (2021) Vol. 35, Iss. 8, pp. 907-918
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections
Annette Langer‐Gould, Bonnie H. Li, Jessica Smith, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 23
Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD
Veronica Mears, Collin Jakubecz, Catherine N. Seeco, et al.
Journal of Neuroimmunology (2023) Vol. 377, pp. 578066-578066
Closed Access | Times Cited: 26
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Enrique Álvarez, Erin E. Longbrake, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105009-105009
Open Access | Times Cited: 23
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
Anas Elgenidy, Nagham Nader Abdelhalim, Mohammed Al-mahdi Al-kurdi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
Aaron Schuckmann, Falk Steffen, Frauke Zipp, et al.
Med (2023) Vol. 4, Iss. 6, pp. 361-372.e3
Open Access | Times Cited: 21
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
Shiv Saidha, Judith A. Bell, Sydney Harold, et al.
Neurological Sciences (2023) Vol. 44, Iss. 5, pp. 1515-1532
Open Access | Times Cited: 17
Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
Mario Habek, Dominik Piskač, Tereza Gabelić, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 62, pp. 103798-103798
Open Access | Times Cited: 22
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
Xavier Montalbán, Daniel J. Wallace, Mark C. Genovese, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 94, Iss. 1, pp. 1-9
Open Access | Times Cited: 22
Management of multiple sclerosis in older adults: review of current evidence and future perspectives
Kimberly DiMauro, Carol Swetlik, Jeffrey A. Cohen
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 3794-3805
Open Access | Times Cited: 4
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
Maria Cellerino, Giacomo Boffa, Caterina Lapucci, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 4, pp. 2579-2588
Open Access | Times Cited: 27
Safety and Efficacy of Fingolimod and Ocrelizumab in Pediatric Patients with Multiple Sclerosis
Benton Spirek, J. Nicholas Brenton
Pediatric Neurology (2025) Vol. 164, pp. 89-96
Closed Access
Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort
Tommaso Guerra, Francesca Caputo, Antonella Bianco, et al.
Drugs - Real World Outcomes (2025)
Open Access
Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, et al.
Immunity Inflammation and Disease (2025) Vol. 13, Iss. 4
Open Access
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort
S Nobile, Philippe Beauchemin
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024) Vol. 51, Iss. 6, pp. 811-818
Open Access | Times Cited: 3
Neutropaenia complications from Ocrelizumab and Rituximab treatment
Venus Pang, Nabil Seery, Robb Wesselingh, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 81, pp. 105147-105147
Open Access | Times Cited: 7
Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis—A Real-World Scenario
Muriel Schraad, Stefan Runkel, Walter Hitzler, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 296-296
Open Access | Times Cited: 2
Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy
Sean A Freeman, Bruno Lemarchant, Tifanie Alberto, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 6, pp. 1707-1722
Open Access | Times Cited: 4
Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
Lisa Beckers, P. Baeten, Veronica Popescu, et al.
Clinical Immunology (2024) Vol. 259, pp. 109894-109894
Open Access | Times Cited: 1
Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up
Tuğba Erdoğan, Cagri Cansu, Belgin Koçer, et al.
Acta Neurologica Belgica (2024) Vol. 124, Iss. 4, pp. 1385-1391
Closed Access | Times Cited: 1
Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study
Trung Dang Quoc Tran, Leanne Hall, Clare Heal, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000672-e000672
Open Access | Times Cited: 1
Ocrelizumab in people with primary progressive multiple sclerosis: a real-world multicentric study
Magdalena Krbot Skorić, Vanja Bašić Kes, Nevena Grbić, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 89, pp. 105776-105776
Closed Access | Times Cited: 1
Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
Afsaneh Shirani, Olaf Stüve, Anne H. Cross
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 137-153
Closed Access | Times Cited: 3
Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies
Ruixin Deng, Yejun Wu, Lan‐Ping Xu, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 11, pp. 1407-1419
Open Access | Times Cited: 7
Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians
Klara Dyczkowska, Alicja Kalinowska-Łyszczarz
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 1, pp. 90-100
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top